Additional Information
Book Details
Abstract
This completely new and updated issue takes a focused look at addiction psychiatry in three sections: Diagnostics, Therapeutics, and New Directions. Dr. Danovitch, from Cedars-Sinai and Dr. Mariani from Columbia hone in on the most rapidly advancing and relevant areas of addiction for practitioners today, from defining addiction (implications of DSM-V), to genetics and neurobiology, to specific treatment options for a variety of patient populations: for pregnant women, adolescents, and patients suffering from chronic pain, for example. A variety of addiction types are discussed (ie, opioid, stimulant, and cannabis). The issue closes with discussions of emerging trends, systems of care, investigational therapeutics and the role of the criminal justice system.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover\r | Cover | ||
| Addiction | i | ||
| Copyright Page | ii | ||
| Table of Contents | vii | ||
| Contributors | iii | ||
| Preface: Expanding Treatment Potential for Substance Use Disorders | xiii | ||
| Chapter 1. Behavioral Addictions: Where to Draw the Lines? | 279 | ||
| HYPERSEXUAL DISORDER | 280 | ||
| PATHOLOGICAL GAMBLING | 283 | ||
| COMPULSIVE SHOPPING | 287 | ||
| SUMMARY | 291 | ||
| REFERENCES | 291 | ||
| Chapter 2. Advances in Opioid Antagonist Treatment for Opioid Addiction | 297 | ||
| PERSPECTIVE ON OPIOID ANTAGONIST TREATMENT FOR ADDICTION | 297 | ||
| NALTREXONE | 298 | ||
| DEPOT NALTREXONE | 299 | ||
| EXTENDED-RELEASE DEPOT NALTREXONE IN CURRENT PRACTICE | 301 | ||
| COMBINATIONS WITH OTHER MEDICATIONS | 302 | ||
| BEHAVIORAL THERAPIES WITH NALTREXONE | 305 | ||
| THE FUTURE OF EXTENDED-RELEASE DEPOT NALTREXONE TREATMENTFOR ADDICTION | 306 | ||
| REFERENCES | 306 | ||
| Chapter 3. State of the Art Treatments for Cannabis Dependence | 309 | ||
| PHARMACOTHERAPY FOR CANNABIS DEPENDENCE | 312 | ||
| PSYCHOTHERAPY FOR CANNABIS DEPENDENCE | 316 | ||
| SUMMARY | 319 | ||
| REFERENCES | 320 | ||
| Chapter 4. New Systems of Care for Substance Use Disorders: Treatment, Finance, and Technology Under\rHealth Care Reform | 327 | ||
| PREVAILING SYSTEMS OF ADDICTION TREATMENT AND FUNDING | 328 | ||
| EMERGING SYSTEMS OF ADDICTION TREATMENT AND FUNDING | 329 | ||
| IMPLEMENTING AND EXPANDING SYSTEMS OF ADDICTION TREATMENT: CASE STUDIES | 336 | ||
| EMERGING TECHNOLOGY AND INFORMATION MANAGEMENT IN ADDICTION TREATMENT | 345 | ||
| SUMMARY | 347 | ||
| ACKNOWLEDGMENTS | 349 | ||
| FACULTY DISCLOSURE AND CONFLICT OF INTEREST | 349 | ||
| REFERENCES | 349 | ||
| Chapter 5. Serotonergic Hallucinogens and Emerging Targets for Addiction Pharmacotherapies | 357 | ||
| INTRODUCTION | 357 | ||
| A BRIEF HISTORY OF RESEARCH ON SHs | 358 | ||
| LSD AND ALCOHOLISM TREATMENT STUDIES | 359 | ||
| THE NATIVE AMERICAN CHURCH/PEYOTE, THE UNIAO DO VEGETAL/AYAHUASCA, AND ANTI-ADDICTION | 360 | ||
| CLASSIFICATION OF HALLUCINOGENS | 360 | ||
| NEUROBIOLOGY AND MECHANISMS OF ACTION OF SHs | 361 | ||
| ADDICTIVE LIABILITY OF SHs | 362 | ||
| IBOGAINE AND OPIOID WITHDRAWAL; IBOGAINE AND ADDICTION | 362 | ||
| ANTI-ADDICTIVE MECHANISMS OF CHANGE | 364 | ||
| CURRENT STATE OF RESEARCH IN THE UNITED STATES ON SEROTONERGIC HALLUCINOGEN TREATMENT MODELS FOR SUBSTANCE ABUSE | 367 | ||
| SUMMARY | 369 | ||
| REFERENCES | 370 | ||
| Chapter 6. Drug Treatments in Criminal Justice Settings | 375 | ||
| DRUG USE PERSISTS WHILE UNDER CORRECTIONAL SUPERVISION | 376 | ||
| ONGOING DRUG USE IS ASSOCIATED WITH INCREASED CRIME IN THIS POPULATION | 376 | ||
| DRUG USE AS THE PRODUCT OF OPERANT CONDITIONING | 377 | ||
| OPERANT PRINCIPLES HAVE GIVEN RISE TO CONTINGENCY MANAGEMENT TREATMENTS | 377 | ||
| TRANSLATING CONTINGENCY MANAGEMENT TO A CRIMINAL JUSTICE CONTEXT | 378 | ||
| THE USE OF COERCION IN CRIMINAL JUSTICE SETTINGS | 378 | ||
| ADDICTION TREATMENT AND REOFFENDING | 379 | ||
| THE NATIONAL TREATMENT OUTCOME RESEARCH STUDY | 381 | ||
| THE DRUG ABUSE TREATMENT OUTCOMES STUDY | 383 | ||
| DRUG COURTS | 384 | ||
| OTHER STUDIES | 385 | ||
| SUMMARY | 387 | ||
| REFERENCES | 387 | ||
| Chapter 7. Managing Co-Occurring Substance Use and Pain Disorders | 393 | ||
| PAIN CLASSIFICATIONS | 393 | ||
| PSYCHIATRIC EVALUATION OF PAIN AND ADDICTION | 394 | ||
| DIAGNOSIS OF PAIN AND ADDICTION | 395 | ||
| THE EXPANSION OF PRESCRIPTION OPIOID USAGE | 395 | ||
| LESSONS IN THE MANAGEMENT OF CHRONIC PAIN WITH OPIOIDS | 396 | ||
| THE SCOPE OF THE PROBLEMS RELATED TO OPIOID USE | 397 | ||
| PSYCHIATRIC ASSESSMENT | 398 | ||
| UNIVERSAL PRECAUTIONS IN PAIN MEDICINE | 401 | ||
| PHARMACOLOGIC CONSIDERATIONS AND STRATEGIES FOR PAIN | 402 | ||
| SOME TRANSDERMAL TREATMENT OPTIONS | 403 | ||
| DUAL MECHANISM OF ACTION MEDICATIONS | 403 | ||
| MANAGING OPIOID TAPER OR WITHDRAWAL | 404 | ||
| SUMMARY | 405 | ||
| REFERENCES | 406 | ||
| Chapter 8. Clinical Implications of Drug Abuse Epidemiology | 411 | ||
| TRENDS IN SUBSTANCE USE | 412 | ||
| PRESCRIPTION OPIOID MISUSE | 413 | ||
| DRUG ABUSE AND DEPENDENCE | 413 | ||
| SPECIAL POPULATIONS | 414 | ||
| COMORBID PSYCHIATRIC DISORDERS | 414 | ||
| COMORBID HIV INFECTION WITH DRUG USE | 415 | ||
| GENETIC EPIDEMIOLOGY OF DRUG USE DISORDERS | 418 | ||
| SUMMARY | 418 | ||
| REFERENCES | 419 | ||
| Chapter 9. Psychostimulant Treatment of Cocaine Dependence | 425 | ||
| NEUROBIOLOGY OF STIMULANT TREATMENT FOR COCAINE DEPENDENCE | 426 | ||
| STIMULANT PHARMACOTHERAPY FOR COCAINE DEPENDENCE | 428 | ||
| DOPAMINERGIC AUGMENTATION OF CONTINGENCY MANAGEMENT | 433 | ||
| CO-OCCURRING ADHD AND COCAINE DEPENDENCE | 434 | ||
| ADDICTIVE POTENTIAL OF PSYCHOSTIMULANTS | 434 | ||
| PRECAUTIONS IN PRESCRIBING STIMULANT MEDICATIONS | 434 | ||
| SUMMARY | 435 | ||
| REFERENCES | 436 | ||
| Chapter 10. Treatment of Opioid Dependence in the Setting of Pregnancy | 441 | ||
| COMPLICATIONS OF OPIOID DEPENDENCE DURING PREGNANCY | 442 | ||
| IDENTIFICATION OF OPIOID DEPENDENCE IN THE PREGNANT WOMAN | 445 | ||
| DIAGNOSTIC EVALUATION FOR ADDICTION IN PREGNANCY | 446 | ||
| COMPREHENSIVE TREATMENT OF OPIOID DEPENDENCE DURING PREGNANCY | 448 | ||
| PAIN MANAGEMENT FOR LABOR AND DELIVERY | 454 | ||
| POSTPARTUM CONSIDERATIONS | 455 | ||
| NEONATAL ABSTINENCE SYNDROME | 456 | ||
| SUMMARY | 456 | ||
| REFERENCES | 456 | ||
| Chapter 11. Training the Next Generation of \rProviders in Addiction Medicine | 461 | ||
| THE CHALLENGE IN ADDICTION MEDICINE TRAINING | 461 | ||
| THE CURRENT STATE OF ADDICTION MEDICINE TRAINING | 462 | ||
| CURRENT DEFICITS IN ADDICTION MEDICINE TRAINING | 464 | ||
| IMPROVING ADDICTION TRAINING MEDICINE IN MEDICAL SCHOOL | 468 | ||
| IMPROVING ADDICTION MEDICINE TRAINING IN RESIDENCY | 469 | ||
| SCREENING, BRIEF INTERVENTION, AND REFERRAL MODEL FOR TRAINING OF RESIDENTS AND ESTABLISHED PRACTITIONERS | 472 | ||
| FUTURE ROLES FOR PSYCHIATRISTS SPECIALIZING IN ADDICTION MEDICINE, INCLUDING ADDICTION PSYCHIATRISTS | 473 | ||
| THE PSYCHIATRIST SPECIALIZING IN ADDICTION MEDICINE AS PERSONAL PHYSICIAN | 474 | ||
| THE PSYCHIATRIST SPECIALIZING IN ADDICTION MEDICINE AS PCMH TEAM MEMBER | 475 | ||
| SUMMARY | 475 | ||
| REFERENCES | 477 | ||
| Chapter 12. Advances in the Psychosocial Treatment of Addiction: The Role of Technology in the Delivery of Evidence-based\rPsychosocial Treatment | 481 | ||
| EVIDENCE-BASED PSYCHOSOCIAL INTERVENTIONS: DEFINITION AND CHALLENGES ASSOCIATED WITH THEIR IMPLEMENTATION | 482 | ||
| HARNESSING TECHNOLOGY TO DELIVER EVIDENCE-BASED PSYCHOSOCIAL INTERVENTIONS | 483 | ||
| PSYCHOSOCIAL INTERVENTIONS FOR CO-OCCURRING ISSUES | 486 | ||
| MOBILE PSYCHOSOCIAL INTERVENTIONS TARGETING SUDS | 486 | ||
| HIV RISK REDUCTION | 486 | ||
| COMPUTERIZED NEUROCOGNITIVE REMEDIATION/EXECUTIVE FUNCTION THERAPY | 487 | ||
| ADVANTAGES OF TECHNOLOGY TO DELIVER EVIDENCE-BASED INTERVENTIONS | 487 | ||
| EMERGING TECHNOLOGIES | 488 | ||
| SUMMARY | 489 | ||
| REFERENCES | 489 | ||
| Chapte 13. The Genetic Basis of Addictive Disorders | 495 | ||
| HERITABILITY OF ADDICTIONS | 496 | ||
| INTERPLAY BETWEEN GENETIC AND ENVIROMENTAL FACTORS | 501 | ||
| GENOME-WIDE ASSOCIATION STUDIES | 506 | ||
| RARE AND COMMON VARIANTS | 509 | ||
| CLASSIFICATION AND TREATMENT OF ADDICTIONS | 511 | ||
| SUMMARY | 512 | ||
| REFERENCES | 512 | ||
| Chapter 14. Neurobiology of Addiction Insight from Neurochemical Imaging | 521 | ||
| THE NEUROCIRCUITRY OF REWARD IN ADDICTION | 522 | ||
| IMAGING BRAIN RECEPTORS | 522 | ||
| STIMULANT ABUSE AND DOPAMINE RECEPTORS | 524 | ||
| STIMULANT ABUSE AND STRIATAL DOPAMINE TRANSMISSION | 525 | ||
| STIMULANT ABUSE, DOPAMINE TRANSMISSION, AND RESPONSE TO TREATMENT | 526 | ||
| IMAGING STUDIES OF PSYCHOSTIMULANT ABUSE: BEYOND D2 RECEPTORS | 529 | ||
| ALCOHOL DEPENDENCE | 531 | ||
| CANNABIS DEPENDENCE | 533 | ||
| SUMMARY | 534 | ||
| REFERENCES | 534 | ||
| Index | 543 |